H-CYTE, Inc. (HCYT)
OTCMKTS: HCYT · Delayed Price · USD
0.0200
+0.0004 (2.05%)
Jul 5, 2022 12:26 PM - Market open
Company Description
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States.
The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
The company is headquartered in Tampa, Florida.
H-CYTE, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 8 |
Contact Details
Address:
2202 North West Shore Boulevard Tampa, FL 33607 United States | |
| Phone | 888 664 2983 |
Stock Details
| Ticker Symbol | HCYT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1591165 |
| CUSIP Number | 404124109 |
| ISIN Number | US4041241096 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael W. Yurkowsky | Chief Executive Officer and Director |
| Jeremy Daniel | Chief Financial Officer |
| Dr. Tanya Rhodes Ph.D. | Chief Scientific Officer |
| Jeffery Wright CPA, CPA | Controller and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2022 | 8-K | Current report |
| Jun 9, 2022 | 8-K | Current report |
| May 10, 2022 | 8-K | Current report |
| May 4, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Apr 5, 2022 | DEF 14C | Other definitive information statements |
| Apr 4, 2022 | 8-K | Current report |
| Mar 24, 2022 | PRER14C | Information statements |
| Mar 23, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 2, 2022 | 8-K | Current report |
| Feb 25, 2022 | 4 | Statement of changes in beneficial ownership of securities |